Regeneron Pharmaceuticals' Free Cash Flow fell 1328.07% to $922.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 1134.91%. This contributed to the annual value of $4.1 billion for FY2025, which is 1134.91% up from last year.
Regeneron Pharmaceuticals' Free Cash Flow amounted to $922.0 million in Q4 2025, which was down 1328.07% from $1.4 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Free Cash Flow ranged from a high of $3.3 billion in Q3 2021 and a low of $173.5 million during Q2 2024
In the last 5 years, Regeneron Pharmaceuticals' Free Cash Flow had a median value of $931.8 million in 2023 and averaged $1.1 billion.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Free Cash Flow surged by 90500.61% in 2021, and later plummeted by 8517.25% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Free Cash Flow stood at $2.2 billion in 2021, then fell by 29.31% to $1.6 billion in 2022, then plummeted by 46.53% to $838.3 million in 2023, then rose by 26.83% to $1.1 billion in 2024, then fell by 13.28% to $922.0 million in 2025.
Its last three reported values are $922.0 million in Q4 2025, $1.4 billion for Q3 2025, and $925.4 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value